Protagen Protein Services, BioAnalytix Merge into CRO
The companies will merge to offer a broader range of analytical data packages and regulatory support for biopharmaceuticals.
On April 10, 2019, Protagen Protein Services (PPS), a German contract research organization (CRO) specializing in protein analytics, and BioAnalytix, a Cambridge, MA-based provider of biologic development analytical services, announced that the companies will merge into one global CRO.
Under the conditions of the merger, PPS and BioAnalytix will combine their respective analytical platforms, programs, and teams based in the United States and Europe to design, generate, and deliver integrated analytical data packages and scientific, technical, and regulatory support for all stages of biopharmaceutical development, including biosimilars. Services include developability and lead optimization, clone selection and process development, extended characterization and comparability, stability testing for control strategy design and chemistry, manufacturing, and control filings through commercialization, and full GMP testing of commercial products.
“Both companies have shared a similar vision, entrepreneurial agility, and heritage of excellence in supporting leading pharmaceutical companies with high-end analytics and strategic solutions through development,” said Martin Blüggel, founder and CEO of Protagen Protein Services, in a company press release. “We are fascinated to serve our pharma partners more directly in the FDA and EMEA territories and continue our expansion in capacities and capabilities now including BioAnalytix’s innovative areas such as [hydrogen deuterium exchange–mass spectrometry] and in-vivo [critical quality attribute] mapping.”
“The broader platforms will enable us to provide a significantly greater range of analytic data packages and regulatory support here in the US as we strengthen our focus on delivering analytic excellence in advancing, de-risking and accelerating all stages of biotherapeutic development with our pharma partners,” said Kirtland Poss, Founder and CEO of BioAnalytix, in the release.
Source: Protagen Protein Services
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
